Literature DB >> 28879423

Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease.

Veena Theendakara1, Clare A Peters-Libeu1, Dale E Bredesen1,2, Rammohan V Rao3.   

Abstract

The major genetic risk factor for sporadic Alzheimer's disease (AD) is the lipid binding and transporting carrier protein apolipoprotein E, epsilon 4 allele (ApoE4). One of the unsolved mysteries of AD is how the presence of ApoE4 elicits this age-associated, currently incurable neurodegenerative disease. Recently, we showed that ApoE4 acts as a transcription factor and binds to the promoters of genes involved in a range of processes linked to aging and AD disease pathogenesis. These findings point to novel therapeutic strategies for AD and aging, resulting in an extension of human healthspan, the disease-free and functional period of life. Here, we review the effects and implications of the putative transcriptional role of ApoE4 and propose a model of Alzheimer's disease that focuses on the transcriptional nature of ApoE4 and its downstream effects, with the aim that this knowledge will help to define the role ApoE4 plays as a risk factor for AD, aging, and other processes such as inflammation and cardiovascular disease.

Entities:  

Keywords:  Alzheimer’s disease; ApoE4; Apolipoprotein E; Neurodegeneration; Transcription

Mesh:

Substances:

Year:  2017        PMID: 28879423     DOI: 10.1007/s12035-017-0757-2

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  142 in total

Review 1.  The cell biology and physiologic relevance of ApoE recycling.

Authors:  S Fazio; M F Linton; L L Swift
Journal:  Trends Cardiovasc Med       Date:  2000-01       Impact factor: 6.677

2.  Astrocytes down-regulate neuronal beta-amyloid precursor protein expression and modify its processing in an apolipoprotein E isoform-specific manner.

Authors:  B Vincent; J D Smith
Journal:  Eur J Neurosci       Date:  2001-07       Impact factor: 3.386

Review 3.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

Authors:  Robert W Mahley; Karl H Weisgraber; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

4.  Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects.

Authors:  Christina M Lill; Tian Liu; Brit-Maren M Schjeide; Johannes T Roehr; Denis A Akkad; Vincent Damotte; Antonio Alcina; Miguel A Ortiz; Rafa Arroyo; Aitzkoa Lopez de Lapuente; Paul Blaschke; Alexander Winkelmann; Lisa-Ann Gerdes; Felix Luessi; Oscar Fernadez; Guillermo Izquierdo; Alfredo Antigüedad; Sabine Hoffjan; Isabelle Cournu-Rebeix; Silvana Gromöller; Hans Faber; Maria Liebsch; Esther Meissner; Coralie Chanvillard; Emmanuel Touze; Fernando Pico; Philippe Corcia; Thomas Dörner; Elisabeth Steinhagen-Thiessen; Lars Baeckman; Hauke R Heekeren; Shu-Chen Li; Ulman Lindenberger; Andrew Chan; Hans-Peter Hartung; Orhan Aktas; Peter Lohse; Tania Kümpfel; Christian Kubisch; Joerg T Epplen; Uwe K Zettl; Bertrand Fontaine; Koen Vandenbroeck; Fuencisla Matesanz; Elena Urcelay; Lars Bertram; Frauke Zipp
Journal:  J Med Genet       Date:  2012-09       Impact factor: 6.318

5.  An apolipoprotein E synthetic peptide selectively modulates the transcription of the gene for rat ovarian theca and interstitial cell P450 17alpha-hydroxylase, C17-20 lyase.

Authors:  G Zhang; L K Curtiss; R L Wade; C A Dyer
Journal:  J Lipid Res       Date:  1998-12       Impact factor: 5.922

6.  ApoE 4 reduces the expression of Abeta degrading enzyme IDE by activating the NMDA receptor in hippocampal neurons.

Authors:  Jing Du; Junlei Chang; Songxi Guo; Qing Zhang; Zhao Wang
Journal:  Neurosci Lett       Date:  2009-07-16       Impact factor: 3.046

7.  Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women.

Authors:  S Lehtinen; T Lehtimäki; T Sisto; J P Salenius; M Nikkilä; H Jokela; T Koivula; F Ebeling; C Ehnholm
Journal:  Atherosclerosis       Date:  1995-04-07       Impact factor: 5.162

8.  Human apolipoprotein E4 modulates the expression of Pin1, Sirtuin 1, and Presenilin 1 in brain regions of targeted replacement apoE mice.

Authors:  F Lattanzio; L Carboni; D Carretta; R Rimondini; S Candeletti; P Romualdi
Journal:  Neuroscience       Date:  2013-10-23       Impact factor: 3.590

Review 9.  All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.

Authors:  Jaya Sangodkar; Caroline C Farrington; Kimberly McClinch; Matthew D Galsky; David B Kastrinsky; Goutham Narla
Journal:  FEBS J       Date:  2015-11-14       Impact factor: 5.542

10.  The role of DNA shape in protein-DNA recognition.

Authors:  Remo Rohs; Sean M West; Alona Sosinsky; Peng Liu; Richard S Mann; Barry Honig
Journal:  Nature       Date:  2009-10-29       Impact factor: 49.962

View more
  15 in total

1.  Analysis of differential gene expression and transcript usage in hippocampus of Apoe null mutant mice: Implications for Alzheimer's disease.

Authors:  Andrew E Weller; Glenn A Doyle; Benjamin C Reiner; Richard C Crist; Wade H Berrettini
Journal:  Neurosci Res       Date:  2021-10-29       Impact factor: 3.304

2.  C/EBPβ is a key transcription factor for APOE and preferentially mediates ApoE4 expression in Alzheimer's disease.

Authors:  Yiyuan Xia; Zhi-Hao Wang; Jichun Zhang; Xia Liu; Shan Ping Yu; Karen X Ye; Jian-Zhi Wang; Keqiang Ye; Xiao-Chuan Wang
Journal:  Mol Psychiatry       Date:  2020-12-18       Impact factor: 15.992

3.  Dysregulation of Neuronal Iron Homeostasis as an Alternative Unifying Effect of Mutations Causing Familial Alzheimer's Disease.

Authors:  Amanda L Lumsden; Jack T Rogers; Shohreh Majd; Morgan Newman; Greg T Sutherland; Giuseppe Verdile; Michael Lardelli
Journal:  Front Neurosci       Date:  2018-08-13       Impact factor: 4.677

Review 4.  APOE Alleles and Diet in Brain Aging and Alzheimer's Disease.

Authors:  Hussein N Yassine; Caleb E Finch
Journal:  Front Aging Neurosci       Date:  2020-06-10       Impact factor: 5.750

Review 5.  The Dichotomy of Alzheimer's Disease Pathology: Amyloid-β and Tau.

Authors:  J Wesson Ashford
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 6.  ApoE4: an emerging therapeutic target for Alzheimer's disease.

Authors:  Mirna Safieh; Amos D Korczyn; Daniel M Michaelson
Journal:  BMC Med       Date:  2019-03-20       Impact factor: 8.775

Review 7.  Molecular Insight into the Therapeutic Promise of Targeting APOE4 for Alzheimer's Disease.

Authors:  Abdullah Al Mamun; Md Sahab Uddin; Md Fahim Bin Bashar; Sonia Zaman; Yesmin Begum; Israt Jahan Bulbul; Md Siddiqul Islam; Md Shahid Sarwar; Bijo Mathew; Md Shah Amran; Ghulam Md Ashraf; May N Bin-Jumah; Shaker A Mousa; Mohamed M Abdel-Daim
Journal:  Oxid Med Cell Longev       Date:  2020-05-15       Impact factor: 6.543

8.  The Links between Cardiovascular Diseases and Alzheimer's Disease.

Authors:  Jerzy Leszek; Elizaveta V Mikhaylenko; Dmitrii M Belousov; Efrosini Koutsouraki; Katarzyna Szczechowiak; Małgorzata Kobusiak-Prokopowicz; Andrzej Mysiak; Breno Satler Diniz; Siva G Somasundaram; Cecil E Kirkland; Gjumrakch Aliev
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 9.  Perspectives on the Role of APOE4 as a Therapeutic Target for Alzheimer's Disease.

Authors:  Kavita Patel; Siwangi Srivastava; Shikha Kushwah; Ashutosh Mani
Journal:  J Alzheimers Dis Rep       Date:  2021-12-27

10.  Neuroticism alters the transcriptome of the frontal cortex to contribute to the cognitive decline and onset of Alzheimer's disease.

Authors:  Céline H De Jager; Charles C White; David A Bennett; Yiyi Ma
Journal:  Transl Psychiatry       Date:  2021-02-24       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.